Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?

Gynecologic Oncology

Volumn 86, Issue 3, 2002, Pages 354-357

  Flynn, Paul M ^a,c   Paul, Jim ^b   Cruickshank, Derek J ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b West of Scotland Breast Trial Group   (United Kingdom)

^c UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PLATINUM; TAXANE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PERFORMANCE; PRIORITY JOURNAL; TIME;

EID: 0036444092     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6750     Document Type: Article

References (8)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds). SEER Cancer Statistics Review, 1973-98, Bethesda, MD, National Cancer Institute, 2001.
2. Warwick J, Kehoe S, Earl H, Luesley D, Redman C, Chan KK. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer 1995;72:1513-7.
3. Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J, Reed NS, Kaye SB. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001;84(2):170-8.
4. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000;92(9):699-708.
5. Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R, Thomas H, Davis J, Eggleton SP, Kaye SB. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 1999;17(7):2069-80.
6. Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Davis JA, Reed NS, Crawford SM, MacLean A, Parkin D, Sarkar TK, Kennedy J, Symonds RP. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14(7):2113-9.
7. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Cassidy J, Davis JA, Reed NS, Crawford SM, MacLean A, Swapp GA, Sarkar TK, Kennedy JH, Symonds RP. Randomized study of 2 doses of cisplatin with cyclophos-phamide in epithelial ovarian cancer. Lancet 1992;340(8815):329-33.
8. Cox DR. Regression models and life-tables (with discussion). J R Statist Soc 1972;34:187-220.